Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collaboration and supply agreement with Bayer
Provided updated rinzimetostat combination data in post-abiraterone mCRPC and in post-AR inhibitor mCRPC, consisting of landmark rPFS estimates in both populations that remain consistent with competitor PRC2 inhibitor, and reconfirming a highly differentiated safety profile
Presented potential best-in-class enozertinib data at ESMO Congress 2026, including 84% systemic ORR and 70% CNS ORR, setting a new benchmark in 1L EGFR atypical NSCLC
Announced Redwood-1 global Phase 3 registrational trial in 1L EGFR atypical NSCLC, with initiation expected in 1H 2027
Cash and investments of approximately $345 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout from first Phase 3 trial for rinzimetostat
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today reported financial results and provided operational updates for the quarter ended September 30, 2026, and a rinzimetostat program update.
“Recent clinical data updates reinforce our confidence in the best-in-class potential of our late-stage portfolio, with rinzimetostat continuing to demonstrate an efficacy and safety profile in prostate cancer that is differentiated from current standards of care and the only other PRC2 inhibitor in Phase 3 development, and with enozertinib setting a new benchmark in 1L EGFR atypical NSCLC,” said Jacob M. Chacko, M.D., president and chief executive officer. “With the first Phase 3 trials either underway or planned across both programs and supported by a strong balance sheet, we are laser focused on execution in pursuit of our mission to Overcome Resistance In Cancer."
Third Quarter 2026 and Other Recent Highlights
Rinzimetostat: a potent and selective allosteric inhibitor of PRC2
Second Half 2026 Program Update
The Company conducted a pre-planned biannual Periodic Safety Review (PSR) in October 2026 for the ongoing Phase 1b dose-optimization cohorts evaluating 400 mg QD rinzimetostat in combination with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone and in patients with mCRPC previously treated with an androgen receptor (AR) inhibitor. As of August 14, 2026, with a median follow-up of approximately 8 months, the safety profile across both patient populations was consistent with the prior March 2026 data disclosure; the vast majority of treatment-related adverse events (TRAEs) were Grade 1 in severity and consistent with PRC2 and AR inhibition. The most common TRAEs were fatigue (32%; 11% Grade 1, 16% Grade 2, and 5% Grade 3), diarrhea (24%; 19% Grade 1 and 5% Grade 2), and nausea (22%; 19% Grade 1 and 3% Grade 2), which are similar rates and grades to the March 2026 disclosure. Consistent with the prior disclosure, there were no Grade 4 or 5 adverse events attributed to rinzimetostat or darolutamide. These data continue to demonstrate a highly differentiated safety profile, with significantly lower frequency and severity of adverse events, nearly all Grade 1 or 2, and fewer treatment modifications than competitor regimens.
In parallel with the PSR, longer-term durability was also evaluated across both patient populations.
Additional Rinzimetostat Third Quarter 2026 and Other Recent Highlights
Enozertinib: a brain-penetrant, selective inhibitor targeting EGFR atypical mutations and EGFR exon 20 insertion mutations
ORIC-259: a potent, selective, oral small molecule degrader of CIP2A mRNA
Key Achievements and Anticipated Program Milestones:
Third Quarter 2026 Financial Results
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR atypical and EGFR exon 20 insertion mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the continued clinical development of rinzimetostat and enozertinib; the potential advantages of rinzimetostat and enozertinib; clinical outcomes from studies of rinzimetostat and enozertinib, which may materially change as patient enrollment continues or more patient data become available; the development plans and timelines for rinzimetostat and enozertinib; plans underlying ORIC’s clinical trials and development; anticipated program milestones, including timing of program and data updates; the potential benefits of ORIC’s agreement with CRUK; the period over which ORIC estimates its existing cash and investments will be sufficient to fund its current operating plan; and statements by the company’s chief executive officer. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and ORIC’s limited operating history; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of rinzimetostat, enozertinib or any other product candidates to differ from preclinical, initial, interim, preliminary, expected or prior clinical trial results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements or its clinical trial collaboration and supply agreements; the potential market for ORIC’s product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the SEC) on November 16, 2026, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
All registered trademarks are the property of their respective owners.
|
ORIC PHARMACEUTICALS, INC. CONDENSED BALANCE SHEETS (in thousands) |
||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash, cash equivalents and short-term investments | $ | 261,376 | $ | 281,488 | ||||
| Prepaid expenses and other current assets | 13,375 | 6,978 | ||||||
| Total Fina Elf current assets | 274,751 | 288,466 | ||||||
| Long-term investments | 83,986 | 110,762 | ||||||
| Property and equipment, net | 2,085 | 2,415 | ||||||
| Other assets | 6,064 | 7,247 | ||||||
| Total Fina Elf assets | $ | 366,886 | $ | 408,890 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 2,151 | $ | 3,824 | ||||
| Accrued liabilities | 22,625 | 16,593 | ||||||
| Total Fina Elf current liabilities | 24,776 | 20,417 | ||||||
| Other long-term liabilities | 2,607 | 4,111 | ||||||
| Total Fina Elf liabilities | 27,383 | 24,528 | ||||||
| Total Fina Elf stockholders' equity | 339,503 | 384,362 | ||||||
| Total Fina Elf liabilities and stockholders' equity | $ | 366,886 | $ | 408,890 | ||||
|
ORIC PHARMACEUTICALS, INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (in thousands, except share and per share amounts) |
||||||||||||||||
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 43,358 | $ | 28,773 | $ | 111,091 | $ | 83,962 | ||||||||
| General and administrative | 8,193 | 7,898 | 25,375 | 24,491 | ||||||||||||
| Total Fina Elf operating expenses | 51,551 | 36,671 | 136,466 | 108,453 | ||||||||||||
| Loss from operations | (51,551 | ) | (36,671 | ) | (136,466 | ) | (108,453 | ) | ||||||||
| Other income, net | 3,475 | 4,084 | 11,131 | 9,490 | ||||||||||||
| Net loss | $ | (48,076 | ) | $ | (32,587 | ) | $ | (125,335 | ) | $ | (98,963 | ) | ||||
| Other comprehensive (loss) gain: | ||||||||||||||||
| Unrealized (loss) gain on investments | (673 | ) | 428 | (2,477 | ) | 236 | ||||||||||
| Comprehensive loss | $ | (48,749 | ) | $ | (32,159 | ) | $ | (127,812 | ) | $ | (98,727 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.44 | ) | $ | (0.33 | ) | $ | (1.17 | ) | $ | (1.20 | ) | ||||
| Weighted-average shares outstanding, basic and diluted | 108,178,078 | 98,953,331 | 107,230,989 | 82,808,969 | ||||||||||||